Rampart Bioscience
Jeffrey Bartlett is an accomplished biotechnology professional with extensive expertise in gene therapy and molecular virology. Currently serving as CTO/CIO and Co-Founder at Rampart Bioscience since January 2020, Jeffrey previously held significant roles including Senior Director of Gene Therapy Strategic Development at CSL Behring from September 2017 to October 2023, and Chief Scientific Officer at Calimmune, Inc., where leadership in global R&D programs was emphasized. As Vice President of Research & Development at The Ohio State University, Jeffrey focused on the advancement of cell and gene therapies. An academic background includes positions as Associate Professor in Pediatrics and Molecular Virology, contributing to research in gene transfer technologies and viral vectors. Education credentials include a Ph.D. in Molecular Biology from the University of Pittsburgh School of Medicine and an A.B. in Biology and Art from Middlebury College.
This person is not in any teams
This person is not in any offices
Rampart Bioscience
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies. Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.